TABLE 5
FROM:
Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2
Y Yamaguchi, E Miyahara, A Ohshita, Y Kawabuchi, K Ohta, K Shimizu, K Minami, J Hihara, A Sawamura and T Toge
BACK TO ARTICLETable 5. HLA-DR expression on CEA+ or cytokeratin+ effusion cells
| Surface antigens | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| CEA+ | 7a | 38 | 45 | 75 |
| Cytokeratin+ | 19 | 34 | 50 | 66 |
| CD3+ | 57 | 20 | 41 | 3 |
| HLA-DR+ | 8 | 87 | 47 | 82 |
| HLA-DR+CEA+ | 5 (72b) | 27 (71) | 37 (81) | 68 (91) |
| HLA-DR+cytokeratin+ | 6 (30) | 34 (100) | 39 (78) | 63 (95) |
| Effusion cells were collected before the treatment and stained with antibodies indicated. Flow cytometric analysis was performed on Cytoron. | ||||
| aPercentage of surface antigen-positive cells in effusion cells analysed. | ||||
| b HLA-DR+ cells in CEA+ or cytokeratin+ cells. | ||||
